Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan.

Lee WH, Chu CY, Hsu PC, Su HM, Lin TH, Voon WC, Lai WT, Sheu SH.

Thromb Res. 2013 Aug;132(2):190-5. doi: 10.1016/j.thromres.2013.01.036. Epub 2013 Feb 19.

PMID:
23433530
2.
3.

The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial.

Jeng JS, Sun Y, Lee JT, Lin RT, Chen CH, Po HL, Lin HJ, Liu CH, Sun MH, Sun MC, Chern CM, Lien LM, Chiu HC, Hu HH, Chiou HY, Chen ST, Ma H, Hsu CY; SPAD Study Investigators.

Int J Stroke. 2015 Jan;10(1):123-7. doi: 10.1111/ijs.12384. Epub 2014 Nov 14.

PMID:
25394855
4.

Benefit of cilostazol in patients with high risk of bleeding: subanalysis of cilostazol stroke prevention study 2.

Uchiyama S, Shinohara Y, Katayama Y, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C.

Cerebrovasc Dis. 2014;37(4):296-303. doi: 10.1159/000360811. Epub 2014 May 8.

5.

Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): a randomized double-blind non-inferiority trial.

Lee YS, Bae HJ, Kang DW, Lee SH, Yu K, Park JM, Cho YJ, Hong KS, Kim DE, Kwon SU, Lee KB, Rha JH, Koo J, Han MG, Lee SJ, Lee JH, Jung SW, Lee BC, Kim JS.

Cerebrovasc Dis. 2011;32(1):65-71. doi: 10.1159/000327036. Epub 2011 May 25.

PMID:
21613787
6.

Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke.

Dinicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH, Bangalore S, Messerli FH.

Am J Cardiol. 2013 Oct 15;112(8):1230-4. doi: 10.1016/j.amjcard.2013.05.067. Epub 2013 Jul 2. Review.

PMID:
23827403
8.

Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease.

Ishii H, Aoyama T, Takahashi H, Kumada Y, Kamoi D, Sakakibara T, Umemoto N, Suzuki S, Tanaka A, Ito Y, Murohara T.

J Cardiol. 2016 Feb;67(2):199-204. doi: 10.1016/j.jjcc.2015.05.003. Epub 2015 Jun 11.

9.

Cilostazol may prevent cardioembolic stroke in patients undergoing antiplatelet therapy.

Horie N, Kaminogo M, Izumo T, Hayashi K, Tsujino A, Nagata I.

Neurol Res. 2015 Jul;37(7):619-23. doi: 10.1179/1743132815Y.0000000021. Epub 2015 Mar 23.

PMID:
25798683
10.
11.

Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow P2Y12 Assay.

Maruyama H, Takeda H, Dembo T, Nagoya H, Kato Y, Fukuoka T, Deguchi I, Horiuchi Y, Tanahashi N.

Intern Med. 2011;50(7):695-8. Epub 2011 Apr 1.

12.

A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.

Hsiao FY, Tsai YW, Huang WF, Wen YW, Chen PF, Chang PY, Kuo KN.

Clin Ther. 2009 Sep;31(9):2038-47. doi: 10.1016/j.clinthera.2009.09.005.

PMID:
19843493
13.

Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study.

Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, Li Z, Zhang W, Ding M, Gao X, Fan D, Zeng J, Wong K, Lu C, Xiao J, Yao C; Cilostazol versus Aspirin for Secondary Ischaemic Stroke Prevention cooperation investigators.

Lancet Neurol. 2008 Jun;7(6):494-9. doi: 10.1016/S1474-4422(08)70094-2. Epub 2008 May 2. Erratum in: Lancet Neurol. 2008 Aug;7(8):675.

PMID:
18456558
14.
15.

Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials.

Schleinitz MD, Olkin I, Heidenreich PA.

Am Heart J. 2004 Dec;148(6):990-7.

PMID:
15632883
16.

Use of cilostazol for secondary stroke prevention: an old dog with new tricks?

Ansara AJ, Shiltz DL, Slavens JB.

Ann Pharmacother. 2012 Mar;46(3):394-402. doi: 10.1345/aph.1Q420. Epub 2012 Feb 21. Review.

PMID:
22353234
17.

Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.

Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA; CHARISMA Investigators.

J Am Coll Cardiol. 2007 May 15;49(19):1982-8. Epub 2007 Apr 11.

18.

Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease.

Rao AK, Vaidyula VR, Bagga S, Jalagadugula G, Gaughan J, Wilhite DB, Comerota AJ.

Thromb Haemost. 2006 Dec;96(6):738-43.

PMID:
17139367
19.

Clopidogrel two doses comparative 1-year assessment of safety and efficacy (COMPASS) study in Japanese patients with ischemic stroke.

Uchiyama S, Tanahashi N, Minematsu K; COMPASS (SFY6913) Study Group.

Cerebrovasc Dis. 2012;34(3):229-39. doi: 10.1159/000342655. Epub 2012 Sep 25.

PMID:
23018233
20.

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.

Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, Hacke W, Mak KH, Pearson TA, Boden WE, Steg PG, Flather MD, Montalescot G, Topol EJ; CHARISMA Investigators.

Eur Heart J. 2007 Sep;28(18):2200-7. Epub 2007 Aug 2.

PMID:
17673448

Supplemental Content

Support Center